The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...
S&P 500 dips 0.26% as tech stocks weigh on US indices. Traders eye Nvidia earnings and PCE data for market direction. Read ...
Premium Quality Power IPO Day 2 Highlights: The subscription period for the Quality Power IPO is scheduled from Friday, February 14, to Tuesday, February 18. Quality Power IPO Day 2 Highlights ...
In my opinion, this strategic shift is also aimed at reducing dependence on sales of the Eylea franchise and Dupixent. Currently, the flagship of Regeneron's oncology franchise is Libtayo ...
Copyright 2024 The Associated Press. All rights reserved. Visit our YouTube page (opens in a new tab) Visit our Facebook page (opens in a new tab) Visit our Instagram ...
Click your choice to see results and speak your mind. The Cardiff University-led study demonstrates how a southern shift of the westerly winds and a polar shift of the ACC during prior periods when ...
SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing mounting pressure on multiple fronts. Following disappointing sales figures and ongoing ...
EyePoint Pharmaceuticals, a biotech attempting to grab a sliver of Regeneron’s share of the degenerative eye disease market, said six-month results show its ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call.
Regeneron reported Q4 earnings on Tuesday, with revenues up 10% versus Q4 in 2023. EYLEA HD has stabilized its franchise with a modest sales growth of 1% in 2024 versus 2023. Biosimilar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback